Celyad Oncology SA

CYAD

Company Profile

  • Business description

    Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of innovative technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.

  • Contact

    Rue Edouard Belin 2
    Axis Business Park
    Brabant Wallon
    Mont-Saint-Guibert1435
    BEL

    T: +32 10394100

    E: [email protected]

    https://www.celyad.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    39

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,785.6043.10-0.49%
CAC 407,766.7143.240.56%
DAX 4024,206.91133.240.55%
Dow JONES (US)44,240.76165.60-0.37%
FTSE 1008,854.1847.650.54%
HKSE23,965.79182.28-0.75%
NASDAQ20,418.465.950.03%
Nikkei 22539,791.74102.930.26%
NZX 50 Index12,768.6190.41-0.70%
S&P 5006,225.524.46-0.07%
S&P/ASX 2008,547.3043.40-0.51%
SSE Composite Index3,511.8314.360.41%

Market Movers